Share this to:

Support & Insight for the Autumn of Life

The ABC’s of Alzheimer’s, Bladders and Cholinesterase Inhibitors

Researchers in Houston, Texas find that taking a cholinesterase inhibitor such as donepezil may increase one’s trips to the bathroom. Learn more.


A study from the University of Houston College of Pharmacy, published in the Journal of the American Geriatrics Society, has evaluated the risk of overactive bladder (OAB) as a side effect of cholinesterase inhibitor (ChEI) drugs taken for dementia and Alzheimer’s disease. The research was based on the dissertation work of the study’s first author Prajakta Masurkar.

Dementia is a group of symptoms associated with a decline in memory, reasoning or other thinking skills. Alzheimer’s disease is the most common cause of dementia, accounting for 60% to 80% of cases.

ChEI drugs, including donepezil, galantamine and rivastigmine, increase communication between nerve cells to enhance cognition.

What they found

Using Medicare data, the study examined 524,975 adults (aged 65 and older) with dementia who used ChEIs (donepezil 80.72%, rivastigmine 16.41%, galantamine 2.87%).

“The study found that the risk of overactive bladder varies across individual ChEIs,” reports Rajender R. Aparasu, Mustafa and Sanober Lokhandwala Endowed Professor of Pharmacy and chair, Department of Pharmaceutical Health Outcomes and Policy.

“Using a national cohort of older adults with dementia, we also found that donepezil was associated with a 13% increased risk of OAB compared to rivastigmine, whereas there was no differential risk of OAB with galantamine and rivastigmine.”

Earlier studies support findings

The primary outcome of interest was OAB diagnosis or prescription of antimuscarinics, drugs which help correct overactive bladder, within six months of ChEI initiation.

While some studies have been conducted to evaluate the effects of all ChEIs and antimuscarinic use, few studies have been conducted regarding the effects of individual ChEIs on the risk of OAB.

Previous studies have found that the use of ChEIs is associated with an increased risk of receiving an antimuscarinic drug. But this study opens a new door.

“The findings suggest the need to understand and manage medication-related morbidity in older adults with dementia,” said Aparasu.

SOURCE:

REFERENCE:

  • Prajakta P. Masurkar, Satabdi Chatterjee, Jeffrey T. Sherer, Hua Chen, Michael L. Johnson, Rajender R. Aparasu. Risk of overactive bladder associated with cholinesterase inhibitors in dementia. Journal of the American Geriatrics Society, 2021; DOI: 10.1111/jgs.17579

Subscribe
Notify of
guest

0 Comments
Inline Feedbacks
View all comments
B. Berger

B. Berger

Visit Our Pages On:

Welcome

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Related

a413-Stemcells-W160.jpeg
Princeton Fast-Tracks New Path for Treating Alzheimer's
Princeton University set its sights on preventing amyloid-beta plaque, the most notorious culprit behind Alzheimer's....
1071.jpeg
ClockMe Computerized Dementia Self-Test Created at Georgia Tech
See Georgia Tech's simple-to-use computer program that allows adults to screen themselves for early signs of dementia.
laboratory, analysis, chemistry
FDA Okays Trial of Alzheimer's Pill with Unique Mechanism
The new Alzheimer's injections Aduhelm and Lecanemab offer hope. Now, Mastinimab is trying to break through to the ne...

Books

Amazon Books
0
Would love your thoughts, please comment.x
()
x
News to Get at the Truth

Subscribe To Our Weekly Newsletter

Enjoy thought-provoking videos & articles
News to Get at the Truth

Subscribe To Our Weekly Newsletter